Mifegyne (Mifepristone)

Mifepristone acts as a progesterone receptor antagonist. By blocking progesterone’s action on the uterine lining, it causes decidual breakdown and detachment of the embryo, making the uterus more responsive to prostaglandins that induce uterine contractions.

The specific dose and regimen of Mifegyne are determined by the prescribing clinician based on national guidelines, gestational age, and patient factors. Only a qualified health professional can set the appropriate dosage for each individual case.

Mifegyne is intended for use in early pregnancy termination and is contraindicated in ongoing pregnancy beyond the approved gestational limit. It is not recommended for breastfeeding women because the drug may be excreted in breast milk and could affect the infant.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mifegyne (mifepristone) is the most widely used progesterone receptor antagonist for early medical abortion, offering a high efficacy rate when combined with misoprostol. Alternative agents, such as methotrexate, have different mechanisms and lower success rates for this indication.

Mifegyne should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or direct sunlight to maintain product stability.

Mifegyne is taken orally as a single tablet under medical supervision. After ingestion, a second medication, usually misoprostol, is administered buccally, sublingually, or vaginally according to the prescribed schedule to complete the termination process.

Serious risks include heavy or uncontrolled bleeding, infection, incomplete abortion requiring surgical intervention, and rare allergic reactions. Patients should be instructed to seek immediate medical care if they experience severe abdominal pain, fever, excessive bleeding, or signs of an allergic response.

Mifegyne is contraindicated in women with confirmed or suspected ectopic pregnancy, chronic adrenal failure, long‑term corticosteroid therapy, anticoagulant use, or known hypersensitivity to mifepristone. It should also be avoided in patients with severe medical conditions that preclude safe termination.